Trials / Unknown
UnknownNCT02192736
Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Translational Biosciences · Industry
- Sex
- All
- Age
- 21 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Allogeneic mesenchymal trophic factors (MTF) from human umbilical cord tissue-derived mesenchymal stem cells (UC-MSC) administered intra-nasally to 20 patients is a safe and useful procedure for inducing improvements in pulmonary function and quality of life in patients with asthma.
Detailed description
The proposed study will assess primary safety and secondary efficacy endpoints of allogeneic UC-MSC-derived MTF administered to patients with asthma. Each patient will receive intra-nasal MTF once per week for a period of 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Trophic factors from umbilical cord mesenchymal stem cells |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2020-04-01
- Completion
- 2020-10-01
- First posted
- 2014-07-17
- Last updated
- 2018-06-26
Locations
1 site across 1 country: Panama
Source: ClinicalTrials.gov record NCT02192736. Inclusion in this directory is not an endorsement.